LivaNova reports Q3 adjusted EPS 73c, consensus 64c

Reports Q3 revenue $286.1M, consensus $273.42M. “LivaNova delivered double-digit revenue growth across all regions, improved profitability and achieved important clearances for the Essenz In-Line Blood Monitor in the Q3,” said Bill Kozy, Interim CEO and Board Chair of LivaNova. “Our performance reflects strong execution throughout the organization as demonstrated in all three Business Units. We look forward to building on these results with a firm focus on patients and performance in the Q4 and in 2024.”